Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients.

Sass LR, Khani M, Romm J, Schmid Daners M, McCain K, Freeman T, Carter GT, Weeks DL, Petersen B, Aldred J, Wingett D, Martin BA.

Fluids Barriers CNS. 2020 Jan 21;17(1):4. doi: 10.1186/s12987-019-0164-3.

2.

Defect Engineering of ZnO Nanoparticles for Bioimaging Applications.

Eixenberger JE, Anders CB, Wada K, Reddy KM, Brown RJ, Moreno-Ramirez J, Weltner AE, Karthik C, Tenne DA, Fologea D, Wingett DG.

ACS Appl Mater Interfaces. 2019 Jul 17;11(28):24933-24944. doi: 10.1021/acsami.9b01582. Epub 2019 Jul 3.

PMID:
31173687
3.

ZnO nanoparticle preparation route influences surface reactivity, dissolution and cytotoxicity.

Anders CB, Eixenberger JE, Franco NA, Hermann RJ, Rainey KD, Chess JJ, Punnoose A, Wingett DG.

Environ Sci Nano. 2018 Feb 1;5(2):572-588. doi: 10.1039/C7EN00888K. Epub 2018 Jan 5.

4.

Rapid Dissolution of ZnO Nanoparticles Induced by Biological Buffers Significantly Impacts Cytotoxicity.

Eixenberger JE, Anders CB, Hermann RJ, Brown RJ, Reddy KM, Punnoose A, Wingett DG.

Chem Res Toxicol. 2017 Aug 21;30(8):1641-1651. doi: 10.1021/acs.chemrestox.7b00136. Epub 2017 Aug 11.

5.

A role of ZnO nanoparticle electrostatic properties in cancer cell cytotoxicity.

Wingett D, Louka P, Anders CB, Zhang J, Punnoose A.

Nanotechnol Sci Appl. 2016 Jul 15;9:29-45. doi: 10.2147/NSA.S99747. eCollection 2016.

6.

Serum Proteins Enhance Dispersion Stability and Influence the Cytotoxicity and Dosimetry of ZnO Nanoparticles in Suspension and Adherent Cancer Cell Models.

Anders CB, Chess JJ, Wingett DG, Punnoose A.

Nanoscale Res Lett. 2015 Dec;10(1):448. doi: 10.1186/s11671-015-1158-y. Epub 2015 Nov 17.

7.

Cytotoxicity of ZnO Nanoparticles Can Be Tailored by Modifying Their Surface Structure: A Green Chemistry Approach for Safer Nanomaterials.

Punnoose A, Dodge K, Rasmussen JW, Chess J, Wingett D, Anders C.

ACS Sustain Chem Eng. 2014 Jul 7;2(7):1666-1673. Epub 2014 May 19.

8.

Improving the selective cancer killing ability of ZnO nanoparticles using Fe doping.

Thurber A, Wingett DG, Rasmussen JW, Layne J, Johnson L, Tenne DA, Zhang J, Hanna CB, Punnoose A.

Nanotoxicology. 2012 Jun;6(4):440-52. doi: 10.3109/17435390.2011.587031. Epub 2011 Jun 2.

PMID:
21635174
9.

Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications.

Rasmussen JW, Martinez E, Louka P, Wingett DG.

Expert Opin Drug Deliv. 2010 Sep;7(9):1063-77. doi: 10.1517/17425247.2010.502560. Review.

10.

Electrostatic interactions affect nanoparticle-mediated toxicity to gram-negative bacterium Pseudomonas aeruginosa PAO1.

Feris K, Otto C, Tinker J, Wingett D, Punnoose A, Thurber A, Kongara M, Sabetian M, Quinn B, Hanna C, Pink D.

Langmuir. 2010 Mar 16;26(6):4429-36. doi: 10.1021/la903491z.

PMID:
20000362
11.

The Influences of Cell Type and ZnO Nanoparticle Size on Immune Cell Cytotoxicity and Cytokine Induction.

Hanley C, Thurber A, Hanna C, Punnoose A, Zhang J, Wingett DG.

Nanoscale Res Lett. 2009 Sep 16;4(12):1409-20. doi: 10.1007/s11671-009-9413-8.

12.

Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles.

Hanley C, Layne J, Punnoose A, Reddy KM, Coombs I, Coombs A, Feris K, Wingett D.

Nanotechnology. 2008 Jul 23;19(29):295103. doi: 10.1088/0957-4484/19/29/295103.

13.

Fluorescent dye encapsulated ZnO particles with cell-specific toxicity for potential use in biomedical applications.

Wang H, Wingett D, Engelhard MH, Feris K, Reddy KM, Turner P, Layne J, Hanley C, Bell J, Tenne D, Wang C, Punnoose A.

J Mater Sci Mater Med. 2009 Jan;20(1):11-22. doi: 10.1007/s10856-008-3541-z. Epub 2008 Jul 24.

PMID:
18651111
14.

Selective toxicity of zinc oxide nanoparticles to prokaryotic and eukaryotic systems.

Reddy KM, Feris K, Bell J, Wingett DG, Hanley C, Punnoose A.

Appl Phys Lett. 2007 May 24;90(213902):2139021-2139023.

15.

In vitro and in vivo immunosuppressive activity of a novel anthracycline, 13-deoxy, 5-iminodoxorubicin.

Olson RD, Headley MB, Hodzic A, Walsh GM, Wingett DG.

Int Immunopharmacol. 2007 Jun;7(6):734-43. Epub 2007 Feb 14.

16.

Differential regulation of soluble and membrane CD40L proteins in T cells.

Matthies KM, Newman JL, Hodzic A, Wingett DG.

Cell Immunol. 2006 May;241(1):47-58. Epub 2006 Sep 11.

PMID:
16963006
17.
18.

Divergence in NK cell and cyclic AMP regulation of T cell CD40L expression in asthmatic subjects.

Wingett D, Nielson CP.

J Leukoc Biol. 2003 Oct;74(4):531-41. Epub 2003 Jul 15.

PMID:
12960288
19.

Cyclic AMP differentially modulates CD40L expression on human nai;ve and memory CD4(+) T cells.

Wingett D, Nielson CP.

Biochem Pharmacol. 2002 Oct 1;64(7):1169-78.

PMID:
12234621
21.

A role for CD99 in T cell activation.

Wingett D, Forcier K, Nielson CP.

Cell Immunol. 1999 Apr 10;193(1):17-23.

PMID:
10202109
22.

Regulation of CD40L expression by cyclic AMP: contrasting proinflammatory and inhibitory actions.

Wingett DG, Forcier K, Nielson CP.

Cell Immunol. 1999 Mar 15;192(2):203-12.

PMID:
10087189
23.

CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis.

Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP.

Breast Cancer Res Treat. 1998 Jul;50(1):27-36.

PMID:
9802617
24.

Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E.

Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS.

Cell Growth Differ. 1997 Dec;8(12):1371-80.

25.

Glucocorticoid-mediated inhibition of RANTES expression in human T lymphocytes.

Wingett D, Forcier K, Nielson CP.

FEBS Lett. 1996 Dec 2;398(2-3):308-11.

26.

Treatment of relapsing autoimmune encephalomyelitis with T cell receptor V beta-specific antibodies when proteolipid protein is the autoantigen.

Whitham RH, Wingett D, Wineman J, Mass M, Wegmann K, Vandenbark A, Offner H.

J Neurosci Res. 1996 Jul 15;45(2):104-16.

PMID:
8843028
27.
28.

Expression of the pim-1 protooncogene: differential inducibility between alpha/beta- and gamma/delta-T cells and B cells.

Wingett D, Stone D, Davis WC, Magnuson NS.

Cell Immunol. 1995 Apr 15;162(1):123-30.

PMID:
7704900
29.

Characterization of the testes-specific pim-1 transcript in rat.

Wingett D, Reeves R, Magnuson NS.

Nucleic Acids Res. 1992 Jun 25;20(12):3183-9.

30.

Stability changes in pim-1 proto-oncogene mRNA after mitogen stimulation of normal lymphocytes.

Wingett D, Reeves R, Magnuson NS.

J Immunol. 1991 Nov 15;147(10):3653-9.

PMID:
1940364
31.

Persistent infection of rabbits with bovine leukemia virus associated with development of immune dysfunction.

Wyatt CR, Wingett D, White JS, Buck CD, Knowles D, Reeves R, Magnuson NS.

J Virol. 1989 Nov;63(11):4498-506. Erratum in: J Virol 1990 Apr;64(4):1878.

32.

The perioperative role in practice.

Wingett D.

AORN J. 1978 Nov;28(5):882-3, 888-9. No abstract available.

PMID:
251088

Supplemental Content

Loading ...
Support Center